Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

References

• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918–2925.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Khalaf D, Zou K, Struss WJ, et al. Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥80 years: a retrospective cohort study. J Clin Oncol. 2018;36(15_suppl):5051–5051.
   Web of Science ®Google Scholar
• Shore ND, Saltzstein DR, Sieber PR, et al. Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): results. J Clin Oncol. 2018;36(6_suppl):296–296.
   Web of Science ®Google Scholar
• Khalaf DJ, Sunderland K, Eigl BJ, et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. Eur Urol. 2018;75(6):940–947.
   PubMed Web of Science ®Google Scholar
• Benoist GE, Hendriks RJ, Mulders PFA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55(11):1369–1380.
   PubMed Web of Science ®Google Scholar
• Goodman A. Abiraterone or enzalutamide for newly diagnosed metastatic castrate-resistant prostate cancer? 2018 [cited April 2, 2018]. Available from: http://www.ascopost.com/issues/august-10-2018/abiraterone-or-enzalutamide-in-prostate-cancer/.
   Google Scholar
• US Food and Drug Administration. ZYTIGA – highlights of prescribing information; 2019 [cited October 9, 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202379s027s028lbl.pdf.
   Google Scholar
• US Food and Drug Administration. XTANDI – highlights of prescribing information; 2018 [accessed February 21, 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf.
   Google Scholar
• Behl AS, Ellis LA, Pilon D, et al. Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide. Am Health Drug Benefits. 2017;10(6):296–303.
   PubMed Web of Science ®Google Scholar
• Ellis LA, Lafeuille MH, Gozalo L, et al. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. Am Health Drug Benefits. 2015;8(4):185–195.
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Prostate Cancer Clinical Trials Working Group, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–1159.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29(11):2200–2207.
   PubMed Web of Science ®Google Scholar
• Heller G, Fizazi K, McCormack R, et al. The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clin Cancer Res. 2017;23(8):1967–1973.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36(14):1389–1395.
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–1446.
   PubMed Web of Science ®Google Scholar
• Al-Ali BM, Eredics K, Madersbacher S, et al. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer: adherence, survival and hospitalization analysis of a medical claims database. Wien Klin Wochenschr. 2018;130(21–22):659–664.
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm. 2014;20(5):477–484.
   PubMed Web of Science ®Google Scholar
• LLave SDl, Carpeño L, Benedetti J, et al. Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: the ADOPTA study. J Clin Oncol. 2017;35(15_suppl):e18014–e18014.
   Web of Science ®Google Scholar
• Mohamad Al-Ali B, Kramer G, Madersbacher S, et al. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: analysis of a medical claims database. Wien Klin Wochenschr. 2017;129(11–12):380–384.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):JCO1900799.
   Web of Science ®Google Scholar